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Abstract
Objective—This study examines asthma risk in facilities producing toluene diisocyanate (TDI).
Methods—A total of 197 workers were monitored from 2007 to 2012. TDI air concentrations 
were used to estimate exposures.
Results—The incidence of cases consistent with TDI-induced asthma was 0.009 per person-
years (seven cases) or consistent with TDI-induced asthma or asthma indeterminate regarding 
work-relatedness was 0.012 (nine cases). Increased risk of cases consistent with TDI asthma was 
observed for cumulative (odds ratio [OR] = 2.08, 95% confidence interval [CI] 1.07 to 4.05) per 
logarithm parts per billion-years and peak TDI exposures (OR = 1.18, 95% CI 1.06 to 1.32) 
(logarithm parts per billion). There was a weak association with cumulative and peak exposures 
for decline of short-term forced expiratory volume in one second (FEV1). Asthma symptoms were 
associated with workers noticing an odor of TDI (OR 6.02; 95% CI 1.36 to 26.68).
Conclusions—There is evidence that cumulative and peak exposures are associated with TDI-
induced asthma.
It is estimated that up to 17% of adult-onset asthma may be the result of occupational 
exposure.1–4 Diisocyanates, such as toluene diisocyanate (TDI), are a cause of occupational 
asthma.1,3,5–8 Exposure to TDI can occur in primary production facilities and secondary 
production facilities that produce polyurethane foams and other products.9–11 Occupational 
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exposure to diisocyanates may increase a worker’s risk for health outcomes including 
respiratory symptoms, sensitization to diisocyanates, and asthma.12,13 There is evidence 
from surveillance reports of declining trends in occupational asthma during the 1990s in the 
United States, United Kingdom, Finland, and Canada.7,9–12,14 Reviews of workplace studies 
indicate also that incidence rates of TDI-induced asthma have declined.14,15 These favorable 
trends appear to be related to a reduction in workplace exposures through engineering 
controls and changes in work practices as well as medical surveillance practices.14,15
Occupational surveillance programs are often established for agents with sensitizing 
potential like TDI.3,16 Historically, most high exposures to TDI resulted from accidental 
spills or releases.14,17 Today, exposures in the TDI production facilities are characterized as 
very low.14 We examine a TDI medical surveillance program implemented across three TDI 
production plants in the United States to determine the incidence rate of TDI-induced 
asthma over a 5-year period. We also examine the incidence of asthma indeterminate 
regarding work-relatedness, forced expiratory volume in one second (FEV1) decline over 
any 12-month period, and symptoms of asthma among TDI workers. We estimate the 
association of these health outcomes with cumulative and peak exposure to TDI in these 
plants.
METHODS
Participants
The research methods used in this study are described elsewhere in Cassidy et al.18 Briefly, 
the study participants were recruited from TDI medical surveillance programs at a BASF 
Corporation plant in Geismar, Louisiana, a Covestro LLC (formerly Bayer MaterialScience 
LLC) plant in Baytown, Texas, and a Dow Chemical Company plant in Freeport, Texas. 
Eligible workers included those performing tasks in areas with the potential for TDI 
exposure except for contract employees who were not enrolled in the plants’ existing on-site 
medical surveillance programs. Job tasks with potential or known exposure to TDI included 
workers in production, maintenance, storage and transportation, housekeeping, incident 
response, and laboratory analysis of TDI process samples. Any worker who had experienced 
a TDI incident exposure during the study period was also eligible. Exposure monitoring was 
conducted by tasks performed in the job and more than one task with potential TDI exposure 
could be counted during a single shift for estimating exposures. Enrollment and data 
collection began in June of 2007 and ended in June of 2012. The Dow Chemical Company 
TDI production facility ceased operation in October of 2010, but participants were followed 
through the end of the study. Of 269 eligible workers, 197 volunteered to participate (185 
males and 12 females). The average age at enrollment into the study was 42 years (range: 21 
to 62 years). The mean and standard job tenure at the time of enrollment was 11.8 ± 10.1 
years. Thirty-two participants (15.9%) had been employed for less than 1 year. The average 
number of person-years of observation for study participants was 3.9 person-years and 
ranged from 0.1 to 5.8 person-years. The Institutional Reviews Boards at NIOSH and the 
Dow Chemical Company approved the study protocol and monitored study progress. 
Informed written consent was obtained from all 197 workers before participation.
Collins et al. Page 2
J Occup Environ Med. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Health Outcome Classification Criteria
Some researchers have concluded that the clinical presentation of TDI-induced asthma is 
variable, making it difficult to diagnose and, thus, incidence rates are often unreliable.19–22 
In the present study, new cases of asthma were identified from the medical monitoring at 
each plant by application of standardized annual medical assessment, including spirometry 
and questionnaires on symptoms and exposure. In addition, workers in the study could 
report symptoms consistent with asthma at any time to the plant occupational health staff. If 
symptoms indicated possible asthma or the spirometry results indicated an FEV1 decline of 
350 mL or 10% or more in any 12-month period, further medical evaluation was to be 
performed. A consulting pulmonologist reviewed all the provided occupational exposure and 
medical information, including physiological confirmation from work-related changes, and 
provided a determination for each case as consistent with: asthma, other respiratory disease, 
or normal respiratory status. If consistent with asthma, a category was specified: (1) 
consistent with non-work-related asthma; (2) consistent with work-related asthma (a) 
consistent with TDI-induced asthma, (b) consistent with irritant-induced asthma, or (c) 
consistent with asthma caused by other agent(s); or (3) asthma indeterminate regarding 
work-relatedness indicating that TDI asthma while not definitely identified could not be 
ruled out.
Exposure Assessment
The development of exposure estimates is described in Middendorf et al23 and is briefly 
summarized here. Exposure assessment was conducted at the three plant locations. 
Participants who performed similar tasks that had the potential to produce similar time-
weighted average (TWA) TDI exposures, based on detailed discussions of job descriptions, 
were grouped into plant-level similar exposure groups subsequently referred to as Plant 
SEG. Air samples representing shift length duration TWA exposures and exposures during 
the defined short-term high potential exposure tasks were collected. Air samples were 
collected and analyzed using the Covestro Industrial Hygiene Laboratory Method. All 
workers in a Plant SEG were eligible for sampling whether or not they participated in the 
study. Workers were asked through questionnaires if, during the past 12 months they noticed 
an odor of TDI in their work area.23
TWA Exposures
A method was developed to combine Plant SEGs, which had been determined using job 
titles and other relevant factors based on professional judgment, into data-derived cross-
facility SEGs subsequently referred to as SuperSEGs. To develop the SuperSEGs, the TWA 
exposure results, without regard to the use of respirators for each Plant SEG, were 
categorized into one of the following five categories: <0.1 parts per billion (ppb); 0.1 to <0.5 
ppb; 0.5 to <2 ppb; 2 to <5 ppb; and ≥5 ppb. The bounding categories (<0.1 and ≥5 ppb) 
were chosen because 0.1 ppb is approximately the limit of quantification (LOQ), and 5 ppb 
was the 8-hour TWA-threshold limit value at the time of this study.
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Peak Exposures
Because the high potential exposure tasks were not collected in sufficient numbers to allow 
estimates of peak exposures, we used 95th percentiles of the TWA exposures. The 95th 
percentile for the TWA was determined for each worker by assigning that worker’s highest 
estimate of the 95th percentile among the Plant SEGs in which the worker was employed. 
The range for the estimated 95th percentiles was 0.01 to 19.2 ppb unadjusted for respirator 
use.
Cumulative Exposures
Cumulative TWA exposure estimates for individuals were developed based on the log means 
for the TWA exposure clusters and the length of exposure. The range for the estimated 
cumulative TWA exposure was 0.04 to 21.6 ppb-years unadjusted for respirator use. Because 
detailed work-histories were not available, the length of exposure was based on worker 
reports collected from questionnaires. About one-quarter of the workers stated their first TDI 
exposure date. For the other workers, the potential exposure was assumed to commence with 
the beginning of study when the hire-date preceded the start of the study, or was assumed to 
begin at their hire-date when this occurred after the start of the study.
Analysis
Incidence rates and 95% confidence intervals (95% CIs) for four health outcomes were 
calculated for the entire study period: (1) consistent with TDI-induced asthma, (2) consistent 
with TDI-induced asthma or asthma indeterminate regarding work-relatedness, (3) short-
term FEV1 decline, and (4) symptoms of asthma that met criteria for clinical evaluation. 
Cases of asthma were not formally diagnosed by the consulting pulmonologist and therefore 
they were categorized as “consistent with TDI-induced asthma.” The number of type of 
asthma cases classified by the consulting pulmonologist was the numerator for the first two 
rates. For those in the asthma category, person-years were calculated from the date of first 
completed questionnaire to the date of symptom onset. For participants not classified in an 
asthma category, person-years were calculated from date of the first completed questionnaire 
to date of last questionnaire. The number of workers with a 350-mL or 10% or more decline 
in FEV1 over any 12-month period was the numerator for the incidence of short-term FEV1 
decline.24 The denominator was the number of person-years before the decline in FEV1. The 
number of workers reporting respiratory symptoms that met criteria for further clinical 
evaluation of work-related asthma was the final numerator. Such symptoms include 
reporting any one of the following symptoms at least four times during the past 12 months: 
(1) had wheezing or whistling in the chest; (2) had an attack of chest tightness or shortness 
of breath with wheezing or whistling in the chest; (3) been awakened by coughing, 
wheezing, or chest tightness; (4) felt tightness in the chest for longer than a minute; or (5) 
had chills, fever, cough, and muscle aches. All had at least one of the first four sets of 
symptoms. The number of person-years before symptom onset was the denominator.
A series of logistic regression models examined each of the four health outcomes as the 
dependent variable and independent variables of age, cumulative exposure to TDI, and peak 
exposures. Cumulative and peak TDI exposure were modeled separately. Odds ratios (OR) 
and 95% CIs were calculated for each predictive variable and represent the change in the 
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odds per unit increase in the natural-logarithm. We also provide the predicted probability of 
being a case based on median age of the study workers for various levels of cumulative and 
peak exposures to assess the impact of dose. Both cumulative and logged transformed TDI 
exposures were used in separate models. Parallel analyses were carried out for consistent 
with TDI-induced asthma, asthma indeterminate regarding work-relatedness, short-term 
FEV1 decline, and symptoms of asthma. All analyses were done using SAS 9.3 (SAS 
Institute, Cary, NC).
RESULTS
The incidence rates for asthma are presented in Table 1. There were nine cases consistent 
with asthma and they were identified as consistent with TDI-induced asthma (seven cases) 
or asthma indeterminate regarding work-relatedness (two cases). These classifications reflect 
a determination based on the study protocol, not clinical diagnoses. The rate of consistent 
with TDI-induced asthma was 0.009 per person-years, and the rate of combined consistent 
with TDI-induced asthma or asthma indeterminate regarding work-relatedness was 0.012 per 
person-years. The rate of FEV1 decline of 350 mL or 10% or more in any 12-month period 
was 0.026 per person-years. Seventeen of the 19 workers with FEV1 decline did not have 
findings consistent with asthma. The rate of respiratory symptoms qualifying for clinical 
examination among 23 workers for possible work-related asthma was 0.030 per person-
years.
Of the seven with findings consistent with TDI-induced asthma, four had less than 1 year of 
job tenure (range 1 to 7 months), one had worked for 2 years when beginning participation, 
and the other two had worked at the job for 7 and 8 years. Tenure at the time of an event that 
met criteria for further evaluation for asthma ranged from 3 months to 8 years. Two of the 
seven had less than 1 year tenure at the time of event and one less than 2 years. Of the two 
participants with more than 7 years of job tenure, one had a triggering event at the time of 
intake and the other 4 months from the start of the study.
Table 2 presents the logistic regression results for two models based on either cumulative or 
peak exposures for cases consistent with TDI-induced asthma, consistent with TDI-induced 
asthma or asthma indeterminate regarding work-relatedness, short-term FEV1 decline, and 
symptoms of asthma. We present the models for logged cumulative TDI exposure as these 
models fit these data slightly better than the non-logged cumulative TDI exposure models. 
However, the non-logged cumulative exposures yielded similar results. For cases consistent 
with TDI-induced asthma, the OR for cumulative exposure was 2.08 (95% CI 1.07 to 4.05) 
per logarithm ppb-years and for peak exposures was 1.18 (95% CI 1.06 to 1.32) logarithm 
ppb. For cases consistent with TDI-induced asthma or asthma indeterminate regarding work-
relatedness, the cumulative OR was 1.55 (95% CI 0.92 to 2.64) and the peak OR was 1.13 
(95% CI 1.04 to 1.23). For short-term FEV1 decline, the OR for cumulative exposures was 
1.40 (95% CI 0.99 to 1.97) and the OR for peak exposures was 1.06 (95% CI 1.00 to 1.13). 
Neither cumulative (OR = 1.20, 95% CI 0.87 to 1.66) nor peak (OR = 1.04, 95% CI 0.99 to 
1.11) exposures appear associated with symptoms of asthma. However, we did find that 
workers who reported an odor of TDI while working were much more likely to report 
symptoms of asthma (OR = 6.02, 95% CI 1.36 to 26.68) and have findings consistent with 
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TDI-induced asthma (OR = 3.21, 95% CI 0.38 to 27.32), although the asthma OR is 
imprecise. However, workers who reported an odor of TDI were not more likely to have a 
decline in FEV1 (OR = 0.87, 95% CI 0.33 to 2.35).
Six of the seven participants with findings consistent with TDI-induced asthma reported 
detecting an odor of TDI from 1 to 3 times to weekly in the previous 12 months. Five of the 
seven reported having been in the area of a release of TDI, three 1 to 3 times, one 4 to 11 
times, and one weekly in the previous 12 months. All seven reported either detecting TDI 
odor or having been in the area of a release. For the overall cohort, 85 (43%) ever reported 
detecting an odor of TDI: 36 (18%) 1 to 3 times, 27 (14%) 4 to 11 times, 16 (8%) monthly 
and 6 (3%) weekly in the previous 12 months. Being in the area of a release was ever 
reported by 69 (35%) participants: 1 to 3 times by 49 (24%) participants, 4 to 11 times by 16 
(8%), and monthly by 4 (2%) in the previous 12 months. These responses were collected 
annually during the study.
Tables 3 and 4 present the predicted strength of the effect of cumulative and peak exposures 
respectively. For cumulative exposures in Table 3, comparing the cases consistent with TDI-
induced asthma for cumulative exposure from 5 to 20 ppb-years, results in a 153% predicted 
increase [(0.134 to 0.053)/0.053]. Performing the same calculation for peak exposure in 
Table 4 results in a 962% [(0.138 to 0.013)/0.013] predicted increase of being a case.
DISCUSSION
This study has some important strengths. First, the study was longitudinal in design, which 
allowed us to follow workers for an extended period to simultaneously monitor their 
workplace exposures and potential development of asthma. The study design also allowed 
for estimation of cases consistent with TDI-induced asthma incidence among TDI 
production workers that are more recent than the prior longitudinal studies, which were 
completed before 1975 when exposure to TDI was higher.25–28 Second, the study had an 
extensive exposure monitoring protocol, which allowed us to estimate cumulative exposure 
and potential for peak exposures for all study participants. Third, each of the plants in this 
study had an onsite staffed medical facility that not only collected much of the data for the 
study, but also monitored the health of the study participants helping to ensure accurate and 
timely recording of respiratory symptoms.
There are some limitations to this study. First, the risk of work-related asthma is highest 
within six to 24 months after initial exposure, and the latency period may be much longer.3 
Cassidy et al18 reported that this workforce was employed for a mean of 11.8 years and only 
32 (15.6%) participants had worked for less than 12 months at the beginning of the study 
indicating most workers in the study had long-term potential exposure to TDI. It is also 
possible that workers who developed asthma before the study onset had left employment or 
moved away from TDI exposure. Also, the latency period may not have been exceeded in 
this study and we may have missed additional workers that may develop work-related 
asthma sometime after the study ended. Second, despite the use of one protocol and training 
of staff at each of the three plants, the data completeness and quality varied by plant as the 
data were collected through existing surveillance programs at three separate plants. For 
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example, the clinical evaluation protocol was not fully implemented for most of the 42 
eligible workers.18 Third, contract workers at these plants were not included in the study. It 
is possible that exposures to TDI could have been higher for contract workers than for plant 
employed workers. Fourth, we examined both peak and cumulative exposure as they relate 
to asthma risk. While these two exposure measures are most frequently used in occupational 
studies, some other combination of exposure intensity, frequency, and duration may be more 
relevant for assessing asthma risk. In addition, our study uses the 95th percentile of 
cumulative exposure as an indicator of the potential for peak exposures. We did not formally 
measure peak exposure which may have been higher or lower than the estimates we used. 
Fifth, we used study start date as the date of first exposure for the nearly three-fourths of 
participants who did not provide a date of first exposure to TDI. Thus, some participants 
likely had higher cumulative exposures to TDI than we used in our study. Sixth, although 
this study surveyed all TDI producing facilities in the United States, the study was relatively 
small and thus not able to precisely estimate the incidence of cases consistent with TDI-
induced asthma for all potentially exposed workers. Seventh, the small number of cases 
consistent with TDI-induced asthma made it difficult to employ models to assess the role of 
TDI exposures. Eighth, the clinical evaluation in the study protocol was not applied to all 
possible cases. Therefore the sensitivity and specificity of the determination of asthma and 
TDI-induced asthma is unknown. Ninth, the incidence if TDI-induced asthma may be 
underestimated in this study because workers with lung impairment may be excluded from 
being hired, or once hired may leave work or be transferred if TDI-induced asthma occurs.29 
Finally, measuring asthma incidence is difficult. Although adult asthma rarely resolves, it is 
a condition that sometimes occurs, regresses and then reoccurs, thereby making it difficult to 
determine the precise date of asthma development.3
Our study of 197 workers followed over a 5-year period reported an incidence rate of 0.009 
per person-years (0.9%) for cases consistent with TDI-induced asthma based on seven cases. 
If we also consider the asthma indeterminate regarding work-relatedness the rate increases to 
0.012 per person-years (1.2%). Studies conducted prior to 1980 demonstrated annual 
incidence rates of 5% or higher, but more recent longitudinal studies (those conducted since 
1980) show rates similar to this study.14,27,28,30–33, As a point of reference, background rates 
of adult-onset asthma are estimated to be 0.4% per year.34,35 Nevertheless, TDI-induced 
asthma remains a concern as cases still occur in workplaces with relatively low exposures.
We found weak evidence of an association of short-term FEV1 decline of 350 mL or 10% or 
more in any 12-month period with cumulative exposure. We did not adjust for smoking, 
height, or weight, which are all possible confounding factors. However, a detailed analysis 
including other predictors of longitudinal pulmonary function decline over the course of the 
study, such as smoking, height, and weight, in these same workers in an accompanying 
paper found little evidence of a TDI exposure relationship.24,36 The outcome measure in the 
present study is different than these previous studies. For example, the Wang et al24 analysis 
is a longitudinal analysis of a continuous outcome and the analysis in the present study is a 
cross-sectional analysis of a discrete outcome, a substantial decline in lung function in a 
single year. Also, only two of the 19 workers with short-term FEV1 declines had findings 
consistent with work-related asthma and none of the 19 reported symptoms of asthma on the 
questionnaire.
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Reported symptoms of asthma did not show a relationship with exposure, but did show an 
association with noticing odor of TDI. It may be that these asthma-like symptoms without 
the development of asthma are not related to TDI or represent irritant conditions resulting 
from acute TDI exposure that may resolve quickly. However, it could also be that workers 
with asthma symptoms without findings consistent with TDI-induced asthma are at early 
stages in the latency period for full asthma, or were not evaluated sufficiently to be classified 
as having asthma.
We did find an inhalation exposure association with cases consistent with TDI-induced 
asthma for both cumulative and peak exposures. Two studies of workers in the flexible 
polyurethane foam industry conducted in the early 1990s found occupational asthma 
occurring to some workers with peak exposures of TDI above 20 ppb.26,27 Our study lends 
support to the hypothesis that peak exposures above 20 ppb are a risk factor for cases 
consistent with TDI-induced asthma. A prior study in the TDI manufacturing and 
polyurethane foam industries found that respiratory sensitization occurs mostly among jobs 
where exposures exceeded 20 ppb.14 Middendorf23 estimated that over the 7 years of 
sampling for this study, over 1000 tasks performed resulted in short-term exposures of more 
than 20 ppb, not accounting for respirator use. Accounting for reported respirator use, there 
were none. While our study demonstrates a lower incidence of cases consistent with TDI-
induced asthma than past studies,14 we find more evidence that peak exposures are related to 
increased risk. Despite the relatively low exposures to TDI experienced by the workers in 
this study, we did identify seven cases classified as consistent with TDI-induced asthma, two 
cases of asthma indeterminate regarding work-relatedness and 36 additional cases meriting 
further evaluation. Notwithstanding low TDI exposures in today’s production workplace, 
continued exposure vigilance is necessary. Because TDI-induced asthma may fully resolve 
with early recognition and removal from exposure, strategies to identify potential cases early 
are important to implement.3
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TABLE 1
Incidence Rates for TDI-Induced Asthma, TDI-Induced Asthma or Asthma Indeterminate Regarding Work-
Relatedness, FEV1 Decline, and Respiratory Symptoms
Health Outcomes
for 197 Workers Cases
Incidence Rate (95% CI)
(Cases/Person-years)
TDI-induced asthma 7 0.009 (0.002–0.016)a
TDI-induced asthma or asthma indeterminate regarding work-relatedness 9 0.012 (0.004–0.020)b
FEV1 decline of 350 mL or 10% or more 19 0.026 (0.014–0.037)c
Respiratory symptoms qualifying for clinical examination for possible work-related asthma 23 0.030 (0.018–0.042)d
a765.2 person-years.
b762.7 person-years.
c743.4 person-years.
d755.4 person-years.
CI, confidence interval; FEV1, forced expiratory volume in one second; TDI, toluene diisocyanate.
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TABLE 2
Logistic Regression Results for an Association Between Log Cumulative Exposure to TDI for TDI-Induced 
Asthma, TDI-Induced Asthma or Asthma Indeterminate Regarding Work-Relatedness, FEV1 Decline, and 
Respiratory Symptoms
Variable Estimatea SE P* OR (95% CI)
TDI-induced asthma (seven cases)
  Model 1
    Cumulative exposureb 0.7301 0.34 0.03 2.08 (1.07–4.05)
  Model 2
    Peak exposurec 0.1667 0.06 0.003 1.18 (1.06–1.32)
TDI-induced asthma or indeterminate asthma (nine cases)
  Model 1
    Cumulative exposure 0.4411 0.27 0.10 1.55 (0.92–2.64)
  Model 2
    Peak exposure 0.1235 0.04 0.004 1.13 (1.04–1.23)
FEV1 declined (19 Cases)
  Model 1
    Cumulative exposure 0.3331 0.18 0.06 1.40 (0.99–1.97)
  Model 2
    Peak exposure 0.0598 0.03 0.07 1.06 (1.00–1.13)
Symptoms of asthmae (23 cases)
  Model 1
    Cumulative exposure 0.1840 0.16 0.26 1.20 (0.87–1.66)
  Model 2
    Peak exposure 0.0433 0.03 0.15 1.04 (0.99–1.11)
aAll models adjusted for age (continuous) in years.
b
Log ppb-years.
cppb.
dNone of the workers with TDI-induced asthma or indeterminate asthma had a 10% FEV1 decline in a year.
eAll workers with TDI-induced asthma or indeterminate asthma reported symptoms of asthma.
*P for chi-square test using exact methods.
CI, confidence interval; FEV1, forced expiratory volume in one second; OR, odds ratio; ppb, parts per billion; SE, standard error; TDI, toluene 
diisocyanate.
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TABLE 3
Predicted Probability for Being a Case for Median Age of 42 and Some Selected Levels of Cumulative 
Exposure
Model 1 5 ppb-years 10 ppb-years 15 ppb-years 20 ppb-years
TDI-induced asthma (seven cases)
  Cumulative exposure 0.053 0.085 0.111 0.134
TDI-induced asthma or indeterminate asthma (nine cases)
  Cumulative exposure 0.061 0.081 0.096 0.107
FEV1 decline (19 cases)
  Cumulative exposure 0.147 0.177 0.198 0.213
Symptoms of asthma (23 cases)
  Cumulative exposure 0.143 0.160 0.170 0.178
FEV1, forced expiratory volume in one second; ppb, parts per billion.
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TABLE 4
Predicted Probability for Being a Case for Median Age of 42 and Some Selected Levels of the Estimated 95th 
Percentile for the Workers’ Highest TWA Potential Exposure
Model 2 5 ppb 10 ppb 15 ppb 20 ppb
TDI-induced asthma (seven cases)
  Peak exposure 0.013 0.029 0.065 0.138
TDI-induced asthma or indeterminate asthma (nine cases)
  Peak exposure 0.025 0.045 0.081 0.140
FEV1 decline (19 cases)
  Peak exposure 0.090 0.118 0.153 0.196
Symptoms of asthma (23 cases)
  Peak exposure 0.109 0.132 0.159 0.190
FEV1, forced expiratory volume in one second; ppb, parts per billion; TWA
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